[Macrolides, Pseudomonas aeruginosa and cystic fibrosis].
Long-term low dose azithromycin treatment in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection is safe and reduces the decline in lung function, the number of acute exacerbations and improves nutritional status; underlying efficacy mechanisms are multiple and synergistic.
Guillot
M
M
Service de pédiatrie et CRCM de Lisieux, CHG Robert-Bisson, 4, rue Roger-Aini, 14100 Lisieux, France. m.guillot@ch-lisieux.fr
Amiour
M
M
El Hachem
C
C
Harchaoui
S
S
Ribault
V
V
Paris
C
C
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017963:Azithromycin / Q000627:therapeutic use*; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications*; D006801:Humans; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology
D000900:Anti-Bacterial Agents; D017963:Azithromycin